Higher iPTH Does Not Hike Risk of Death, Cardiovascular Events

Share this content:

This article is part of our ongoing coverage of Renal Week 2009. Click here for a complete list of our Renal Week Live articles.


Key Points

  • Higher intact parathyroid hormone levels are not associated with all-cause mortality and cardiovascular (CV) events in CKD patients not yet on dialysis.
  • It has been hypothesized that elevated iPTH increases the risk of death among CKD patients not yet on dialysis.
  • Investigators evaluated the effects of high doses of folic acid and B vitamins on all-cause mortality and CV events in 1,133 patients with advanced CKD and elevated serum homocysteine levels.

Higher intact parathyroid hormone (iPTH) levels are not associated with all-cause mortality and cardiovascular events in CKD patients not yet on dialysis, researchers have concluded.

It has been hypothesized that elevated iPTH increases the risk of death among CKD patients not yet on dialysis.

In a randomized, double-blind trial, named the Homocysteine Study, Jessica B. Kendrick, MD, of the University of Colorado Health Sciences Center in Denver, and colleagues evaluated the effects of high doses of folic acid and B vitamins on all-cause mortality and CV events in 1,133 patients with advanced CKD and elevated serum homocysteine levels.

During a median follow-up of three years, 472 patients (42%) died from any cause and 237 (21%) had a CV event. After adjusting for potential confounders, the investigators found no association between iPTH and either all-cause mortality or CV events.

The study population had a mean age of 69 years, and 27% of subjects were black.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters